SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Summit Therapeutics Inc. (SMMT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.8) | C (2.4) | B- (3.0) | A+ (5.0) | B- (2.9) |
| 2026-11-07 | C+ (2.5) | D+ (1.6) | C+ (2.5) | B- (3.1) | A+ (5.0) | B- (2.9) |
| 2026-10-31 | C+ (2.5) | D (1.5) | C+ (2.6) | B (3.2) | A+ (5.0) | B- (3.0) |
| 2026-10-24 | C+ (2.5) | D (1.5) | C+ (2.5) | C+ (2.6) | A+ (5.0) | C+ (2.8) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe